Previous close | 1.1200 |
Open | 1.1300 |
Bid | 1.1500 x 100 |
Ask | 1.2400 x 100 |
Day's range | 1.1300 - 1.2100 |
52-week range | 0.5200 - 1.5700 |
Volume | |
Avg. volume | 486,700 |
Market cap | 56.831M |
Beta (5Y monthly) | 3.00 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.3200 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 3.33 |
Key Insights IceCure Medical to hold its Annual General Meeting on 20th of May CEO Eyal Shamir's total compensation...
IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, announced today that positive data from an independent study (the "Study") performed in Japan was published in an article titled "Percutaneous ultrasound–guided cryoablation for early–stage primary breast cancer: a follow–up study in Japan," in the journal Breast Cancer on Ap
IceCure Medical (ICCM) submits final ICE data along with multiple sub-analysis to the FDA seeking approval for marketing authorization for treating early-stage breast cancer.